## Smith Cie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8094389/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia, 2022, 36, 476-481.	7.2	25
2	Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles. Advanced Healthcare Materials, 2022, 11, e2101658.	7.6	28
3	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med, 2022, 3, 137-153.e3.	4.4	19
4	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. Molecular Medicine, 2022, 28, 20.	4.4	18
5	Clinical measurement of cellular DNA damage hypersensitivity in patients with DNA repair defects. Orphanet Journal of Rare Diseases, 2022, 17, 50.	2.7	0
6	Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides. Communications Biology, 2022, 5, 185.	4.4	7
7	Elevated CD21low B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2022, 42, 716-727.	3.8	13
8	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVIDâ€19 in chronic lymphocytic leukaemia?. Scandinavian Journal of Immunology, 2022, 95, e13153.	2.7	5
9	2′- <i>O</i> -( <i>N</i> -(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity. Nucleic Acid Therapeutics, 2022, ,	3.6	4
10	Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. Journal of Clinical Immunology, 2022, 42, 1130-1136.	3.8	13
11	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. Molecular Medicine, 2022, 28, 54.	4.4	18
12	Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. Journal of Experimental Medicine, 2022, 219, .	8.5	21
13	Estimating the number of diseases – the concept of rare, ultra-rare, and hyper-rare. IScience, 2022, 25, 104698.	4.1	15
14	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. Pharmaceutics, 2021, 13, 116.	4.5	5
15	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia, 2021, 35, 1317-1329.	7.2	35
16	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Frontiers in Cell and Developmental Biology, 2021, 9, 630942.	3.7	119
17	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. HemaSphere, 2021, 5, e564.	2.7	15
18	Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Frontiers in Immunology, 2021, 12, 689472.	4.8	32

#	Article	IF	CITATIONS
19	Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. Biomedicines, 2021, 9, 1046.	3.2	6
20	X-linked recessive TLR7 deficiency in $\sim$ 1% of men under 60 years old with life-threatening COVID-19. Science Immunology, 2021, 6, .	11.9	267
21	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. Nucleic Acid Therapeutics, 2021, 31, 443-456.	3.6	4
22	Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. Nature Biomedical Engineering, 2021, 5, 1084-1098.	22.5	41
23	Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors. Frontiers in Immunology, 2021, 12, 804735.	4.8	1
24	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine, 2021, 74, 103705.	6.1	161
25	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells. Cancers, 2020, 12, 1143.	3.7	7
26	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. Blood Advances, 2020, 4, 2439-2450.	5.2	15
27	Chemical Development of Therapeutic Oligonucleotides. Methods in Molecular Biology, 2019, 2036, 3-16.	0.9	14
28	Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1568-1577.	3.8	40
29	Precursor B-cell development in bone marrow of Good syndrome patients. Clinical Immunology, 2019, 200, 39-42.	3.2	14
30	Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases. Neurotherapeutics, 2019, 16, 248-262.	4.4	18
31	Oligonucleotide Binding to Non-B-DNA in MYC. Molecules, 2019, 24, 1000.	3.8	5
32	Oligonucleotide–Palladacycle Conjugates as Splice-Correcting Agents. Molecules, 2019, 24, 1180.	3.8	10
33	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. PLoS ONE, 2019, 14, e0211651.	2.5	7
34	Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting ETV6. Blood Advances, 2019, 3, 2722-2731.	5.2	10
35	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. Pharmaceutics, 2019, 11, 666.	4.5	10
36	Therapeutic Oligonucleotides: State of the Art. Annual Review of Pharmacology and Toxicology, 2019, 59, 605-630.	9.4	208

#	Article	IF	CITATIONS
37	Kappaâ€deleting recombination excision circle levels remain low or undetectable throughout life in patients with Xâ€linked agammaglobulinemia. Pediatric Allergy and Immunology, 2018, 29, 453-456.	2.6	6
38	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression. Biochemical and Biophysical Research Communications, 2018, 504, 749-752.	2.1	8
39	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 29-40.	4.3	17
40	lbrutinib induces rapid downâ€regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemiaâ€related genes in blood and lymph nodes. British Journal of Haematology, 2018, 183, 212-224.	2.5	13
41	Role of Pseudoisocytidine Tautomerization in Triplex-Forming Oligonucleotides: In Silico and in Vitro Studies. ACS Omega, 2017, 2, 2165-2177.	3.5	9
42	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. Nucleic Acids Research, 2017, 45, 5153-5169.	14.5	19
43	Specific dsDNA recognition by a mimic of the DNA binding domain of the c-Myc/Max transcription factor. Chemical Communications, 2017, 53, 6653-6656.	4.1	14
44	LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. Scientific Reports, 2017, 7, 11043.	3.3	28
45	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). Seminars in Cancer Biology, 2017, 45, 36-49.	9.6	11
46	ANKRD54 preferentially selects Bruton's Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. PLoS ONE, 2017, 12, e0174909.	2.5	2
47	B Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA Processing. PLoS ONE, 2016, 11, e0160255.	2.5	33
48	Disruption of Higher Order DNA Structures in Friedreich's Ataxia (GAA)n Repeats by PNA or LNA Targeting. PLoS ONE, 2016, 11, e0165788.	2.5	18
49	Wnt/β-Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. Stem Cell Reports, 2016, 6, 607-617.	4.8	20
50	Cells release subpopulations of exosomes with distinct molecular and biological properties. Scientific Reports, 2016, 6, 22519.	3.3	728
51	Four Novel Splice-Switch Reporter Cell Lines: Distinct Impact of Oligonucleotide Chemistry and Delivery Vector on Biological Activity. Nucleic Acid Therapeutics, 2016, 26, 381-391.	3.6	12
52	Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency. Molecular Therapy - Nucleic Acids, 2016, 5, e290.	5.1	17
53	Next-generation bis-locked nucleic acids with stacking linker and $2\hat{a}\in^2$ -glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. Nucleic Acids Research, 2016, 44, 2007-2019.	14.5	24
54	Clickable trimethylguanosine cap analogs modified within the triphosphate bridge: synthesis, conjugation to RNA and susceptibility to degradation. RSC Advances, 2016, 6, 8317-8328.	3.6	9

#	Article	IF	CITATIONS
55	A murine model of acute myeloid leukemia withEvi1overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells. Leukemia and Lymphoma, 2016, 57, 183-192.	1.3	1
56	Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. Journal of Extracellular Vesicles, 2015, 4, 26316.	12.2	1,077
57	Characterization of All Possible Single-Nucleotide Change Caused Amino Acid Substitutions in the Kinase Domain of Bruton Tyrosine Kinase. Human Mutation, 2015, 36, 638-647.	2.5	39
58	Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides. Nucleic Acid Therapeutics, 2015, 25, 65-77.	3.6	18
59	Oligonucleotide Therapies: The Past and the Present. Human Gene Therapy, 2015, 26, 475-485.	2.7	220
60	Cyclodextrin–peptide conjugates for sequence specific DNA binding. Organic and Biomolecular Chemistry, 2015, 13, 5273-5278.	2.8	14
61	Sequence-selective DNA recognition and enhanced cellular up-take by peptide–steroid conjugates. Chemical Communications, 2015, 51, 17552-17555.	4.1	8
62	Safety and efficacy of DNA vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 1306-1308.	3.3	45
63	Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. Molecular Therapy - Nucleic Acids, 2014, 3, e172.	5.1	3
64	Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. Molecular Therapy - Nucleic Acids, 2014, 3, e140.	5.1	28
65	Btk29A Promotes Wnt4 Signaling in the Niche to Terminate Germ Cell Proliferation in <i>Drosophila</i> . Science, 2014, 343, 294-297.	12.6	45
66	Design and Application of Bispecific Splice-Switching Oligonucleotides. Nucleic Acid Therapeutics, 2014, 24, 13-24.	3.6	5
67	Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. Journal of Clinical Investigation, 2014, 124, 4067-4081.	8.2	39
68	Diagnostics of Primary Immunodeficiency Diseases: A Sequencing Capture Approach. PLoS ONE, 2014, 9, e114901.	2.5	73
69	Synthesis and evaluation of stability of m3G-CAP analogues in serum-supplemented medium and cytosolic extract. Bioorganic and Medicinal Chemistry, 2013, 21, 7921-7928.	3.0	10
70	Biological Activity and Biotechnological Aspects of Locked Nucleic Acids. Advances in Genetics, 2013, 82, 47-107.	1.8	82
71	Agammaglobulinemia: causative mutations and their implications for novel therapies. Expert Review of Clinical Immunology, 2013, 9, 1205-1221.	3.0	26
72	Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. Nucleic Acids Research, 2013, 41, 3257-3273.	14.5	25

#	Article	IF	CITATIONS
73	Capping of oligonucleotides with "clickable―m3G-CAPs. RSC Advances, 2012, 2, 12949.	3.6	17
74	Differential Evolutionary Wiring of the Tyrosine Kinase Btk. PLoS ONE, 2012, 7, e35640.	2.5	3
75	Circular RNA interference effector molecules (WO10084371). Expert Opinion on Therapeutic Patents, 2011, 21, 115-119.	5.0	2
76	Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 2011, 39, 3972-3987.	14.5	262
77	A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo. Molecular Therapy, 2011, 19, 1457-1467.	8.2	94
78	Optimizing anti-gene oligonucleotide â€~Zorro-LNA' for improved strand invasion into duplex DNA. Nucleic Acids Research, 2011, 39, 1142-1154.	14.5	29
79	Formulation and Delivery of Splice-Correction Antisense Oligonucleotides by Amino Acid Modified Polyethylenimine. Molecular Pharmaceutics, 2010, 7, 652-663.	4.6	27
80	Non-viral nanovectors for gene delivery: factors that govern successful therapeutics. Expert Opinion on Drug Delivery, 2010, 7, 721-735.	5.0	47
81	Phosphatidylinositol-3-kinase-dependent phosphorylation of SLP-76 by the lymphoma-associated ITK-SYK fusion-protein. Biochemical and Biophysical Research Communications, 2009, 390, 892-896.	2.1	11
82	Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3. Clinical and Experimental Immunology, 2008, 90, 199-203.	2.6	12
83	Expression profiling of chicken DT40 lymphoma cells indicates clonal selection of knockout and gene reconstituted cells. Biochemical and Biophysical Research Communications, 2008, 377, 584-588.	2.1	4
84	Building Biologically Active Nucleic Acid Nanocomplexes. Nucleic Acids Symposium Series, 2008, 52, 27-28.	0.3	1
85	Phylogeny of Tec Family Kinases: Identification of a Premetazoan Origin of Btk, Bmx, Itk, Tec, Txk, and the Btk Regulator SH3BP5. Advances in Genetics, 2008, 64, 51-80.	1.8	27
86	Self-Assembling Supramolecular Complexes by Single-Stranded Extension from Plasmid DNA. Oligonucleotides, 2007, 17, 80-94.	2.7	11
87	Zorro locked nucleic acid induces sequenceâ€specific gene silencing. FASEB Journal, 2007, 21, 1902-1914.	O.5	24
88	50 Potential Role of Bruton's Tyrosine Kinase in Toll-like Receptor 9 Mediated Cytokine Production from B Cells. Cytokine, 2007, 39, 14.	3.2	0
89	BTKbase: the mutation database for X-linked agammaglobulinemia. Human Mutation, 2006, 27, 1209-1217.	2.5	176
90	Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored "Bioplex―formation. New Biotechnology, 2005, 22, 185-192.	2.7	17

#	Article	IF	CITATIONS
91	Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. International Journal of Cancer, 2005, 117, 418-430.	5.1	36
92	Inducible H1 Promoter-Driven Lentiviral siRNA Expression by Stuffer Reporter Deletion. Oligonucleotides, 2005, 15, 139-144.	2.7	15
93	Functional replacement ofDrosophilaBtk29A with human Btk in male genital development and survival. FEBS Letters, 2005, 579, 4131-4137.	2.8	19
94	Cooperative strand invasion of supercoiled plasmid DNA by mixed linear PNA and PNA–peptide chimeras. New Biotechnology, 2004, 21, 51-59.	2.7	21
95	Gene therapy of monogenic and cardiovascular disorders. Expert Opinion on Biological Therapy, 2003, 3, 941-949.	3.1	6
96	The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. BioEssays, 2001, 23, 436-446.	2.5	266
97	Proximal promoter of the murine syndecan-1 gene is not sufficient for the developmental pattern of syndecan expression in B lineage cells. American Journal of Hematology, 2001, 67, 20-26.	4.1	5
98	Microphthalmia, facial anomalies, microcephaly, thumb and hallux hypoplasia, and agammaglobulinemia. American Journal of Medical Genetics Part A, 2001, 101, 209-212.	2.4	14
99	In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. Gene Therapy, 2001, 8, 84-87.	4.5	57
100	BTK mediated apoptosis, a possible mechanism for failure to generate high titer retroviral producer clones. Journal of Gene Medicine, 2000, 2, 204-209.	2.8	18
101	The cellular phenotype conditions Btk for cell survival or apoptosis signaling. Immunological Reviews, 2000, 178, 49-63.	6.0	32
102	A peptide nucleic acid–nuclear localization signal fusion that mediates nuclear transport of DNA. Nature Biotechnology, 1999, 17, 784-787.	17.5	386
103	Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Therapy, 1999, 6, 12-21.	4.5	161
104	Mutations of the humanBTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia. Human Mutation, 1999, 13, 280-285.	2.5	91
105	Intercellular spread of GFP-VP22. Journal of Gene Medicine, 1999, 1, 275-279.	2.8	47
106	Intercellular spread of GFPâ€VP22. Journal of Gene Medicine, 1999, 1, 275-279.	2.8	2
107	Thermal unfolding of small proteins with SH3 domain folding pattern. , 1998, 31, 309-319.		51
108	X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase. Seminars in Immunopathology, 1998, 19, 369-381.	4.0	23

#	Article	IF	CITATIONS
109	An Academic Centre for Gene Therapy Research with Clinical Grade Manufacturing Capability. Annals of Medicine, 1997, 29, 579-583.	3.8	5
110	Suicide genes and bystander killing: local and distant effects. Gene Therapy, 1997, 4, 273-274.	4.5	22
111	Direct and sequential switching from μ to ɛ in patients withSchistosoma mansoni infection and atopic dermatitis. European Journal of Immunology, 1997, 27, 130-135.	2.9	20
112	B cell-deficient μMT mice as an experimental model forMycoplasma infections in X-linked agammaglobulinemia. European Journal of Immunology, 1997, 27, 2118-2121.	2.9	17
113	Registries of immunodeficiency patients and mutations. Human Mutation, 1997, 10, 261-267.	2.5	8
114	Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. , 1997, 71, 624-629.		44
115	X-Linked Agammaglobulinemia A Clinical and Molecular Analysis. Medicine (United States), 1996, 75, 287-299.	1.0	222
116	Bclâ€2 rearrangements with breakpoints in both vcr and mbr in nonâ€Hodgkin's lymphomas and chronic lymphocytic leukaemia. British Journal of Haematology, 1996, 92, 647-652.	2.5	22
117	X-linked agammaglobulinemia (XLA): A genetic tyrosine kinase (Btk) disease. BioEssays, 1996, 18, 825-834.	2.5	66
118	Characterization of Haemophilus influenzae Isolates from the Respiratory Tract of Patients with Primary Antibody Deficiencies: Evidence for Persistent Colonizations. Scandinavian Journal of Infectious Diseases, 1995, 27, 303-313.	1.5	25
119	Retroviral-Mediated Gene Transfer of CD34-Enriched Bone Marrow and Peripheral Blood Cells During Autologous Stem Cell Transplantation for Multiple Myeloma. Huddinge Hospital and Karolinska Institute, Huddinge, Sweden. Human Gene Therapy, 1994, 5, 1279-1286.	2.7	17
120	X-Linked Agammaglobulinemia and Other Immunoglobulin Deficiencies. Immunological Reviews, 1994, 138, 159-183.	6.0	120
121	T-cell receptor β gene rearrangements in leukaemic B-cells from patients with chronic lymphocytic leukaemia: association with chromosome 6 deletions. British Journal of Haematology, 1994, 86, 291-297.	2.5	7
122	The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature, 1993, 361, 226-233.	27.8	1,400
123	Specificity and levels of oral and systemic antibodies to Actinobacillus actinomycetemcomitans. Journal of Clinical Periodontology, 1993, 20, 746-751.	4.9	15
124	Analysis of genetic variables in selective human IgG3 deficiency. Tissue Antigens, 1993, 41, 267-268.	1.0	0
125	A 40â€baseâ€pair duplication in the gp91â€ <i>phox</i> gene leading to Xâ€linked chronic granulomatous disease. European Journal of Haematology, 1993, 51, 218-222.	2.2	13
126	Immunoglobulin production in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood mononuclear cells. European Journal of Immunology, 1992, 22, 823-828.	2.9	93

#	Article	IF	CITATIONS
127	TGF-β1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes. International Immunology, 1991, 3, 1099-1106.	4.0	117
128	Humoral Immunity in scid Mice Reconstituted with Cells from Immunoglobulin-Deficient or Normal Humans. Immunological Reviews, 1991, 124, 113-138.	6.0	38
129	Biological half-life of normal and truncated human IgG3 in scid mice. European Journal of Immunology, 1991, 21, 1319-1322.	2.9	16
130	Different amino acids at position 57 of the HLA-DQβ chain associated with susceptibility and resistance to IgA deficiency. Nature, 1990, 347, 289-290.	27.8	103
131	Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics, 1990, 31, 285-290.	2.4	82
132	Transcription, translation and secretion of both IgA subclasses in polyclonally activated human lymphocytes. European Journal of Immunology, 1990, 20, 977-982.	2.9	10
133	Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. European Journal of Immunology, 1989, 19, 1311-1315.	2.9	293
134	CORRELATION BETWEEN DEFICIENCY OF IMMUNOGLOBULIN SUBCLASS G3 AND Gm ALLOTYPE. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology, 1986, 94C, 187-191.	0.2	13
135	No Significant Correlation of HLA—B8 and Amount of Antibodies Directed to Acetylcholine Receptor Protein in Patients with Myasthenia Gravis. Tissue Antigens, 1978, 12, 387-395.	1.0	9
136	No Significant Association between HLA and Bell's Palsy. Tissue Antigens, 1978, 12, 404-406.	1.0	8